甲状腺疾病患者血清胰岛素样生长因子II（IGF-II）浓度的变化。

Change in serum concentration of insulin-like growth factor II (IGF-II) in patients with thyroid disease.

作者信息

Tada H, Watanabe Y, Futakuchi Y, Amino N

机构信息

Department of Laboratory Medicine, Osaka University Medical School, Japan.

出版信息

Endocr J. 1994 Oct;41(5):541-5. doi: 10.1507/endocrj.41.541.

DOI:10.1507/endocrj.41.541

PMID:7889114

Abstract

We investigated the serum concentration of IGF-II in patients with thyroid diseases (25 with untreated Graves' patients, 30 with hypothyroidism, 23 with thyroid adenoma) and in 72 healthy adults as normal controls, by a sensitive radioimmunoassay of serum IGF-II. Thyroid hormones are known to increase IGF-I production in the liver through the enhancement of GH secretion. In case of IGF-II, however, knowledge has been rather limited. The mean +/- SD concentration in healthy subjects was 556 +/- 94 micrograms/L with neither sex nor age dependence. In untreated Graves' patients, serum IGF-II levels (675 +/- 129 micrograms/L) were significantly (P < 0.01) higher than in normal controls, and significantly lower in patients with hypothyroidism (460 +/- 106 micrograms/L; P < 0.01). Thyroid hormones revealed positive correlation with the IGF-II concentration.

摘要

我们通过一种灵敏的血清胰岛素样生长因子-II（IGF-II）放射免疫测定法，对甲状腺疾病患者（25例未经治疗的格雷夫斯病患者、30例甲状腺功能减退患者、23例甲状腺腺瘤患者）以及72名健康成年人作为正常对照进行了血清IGF-II浓度的研究。已知甲状腺激素可通过增强生长激素（GH）分泌来增加肝脏中IGF-I的产生。然而，对于IGF-II，相关知识相当有限。健康受试者的平均±标准差浓度为556±94微克/升，无性别和年龄依赖性。在未经治疗的格雷夫斯病患者中，血清IGF-II水平（675±129微克/升）显著高于正常对照（P<0.01），而在甲状腺功能减退患者中则显著降低（460±106微克/升；P<0.01）。甲状腺激素与IGF-II浓度呈正相关。